Circulating angiopoietin-2 levels increase with progress of chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2571-2576

  David, Sascha ^a,b   Kümpers, Philipp ^a,c   Lukasz, Alexander ^a   Fliser, Danilo ^d   Martens Lobenhoffer, Jens ^e   Bode Böger, Stefanie M ^e   Kliem, Volker ^f   Haller, Hermann ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f Lower Saxony Center for Nephrology   (Germany)

Author keywords

angiopoietin; CKD; dialysis; kidney donation; nephrectomy

Indexed keywords

ANGIOPOIETIN 2; CYSTATIN C; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATE; ARGININE; BIOLOGICAL MARKER; N,N-DIMETHYLARGININE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INULIN CLEARANCE; KIDNEY DONOR; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; AGED; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHRONIC DISEASE; COMPLICATION; DONOR; KIDNEY DISEASE; MIDDLE AGED; NEPHRECTOMY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ADULT; AGED; ANGIOPOIETIN-2; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NEPHRECTOMY; RISK FACTORS; TISSUE DONORS;

EID: 77954764513     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq060     Document Type: Article

References (38)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047 (Pubitemid 350074801)
2. Lameire N, Jager K, Van Biesen W et al. Chronic kidney disease: a European perspective. Kidney Int Suppl 2005:S30-38
3. Zoccali C. The burden of cardiovascular disease in patients with chronic kidney disease and in end-stage renal disease. Contrib Nephrol 2008; 161: 63-67
4. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41: 11-17
5. Kilpatrick RD, McAllister CJ, Kovesdy CP et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: 293-303
6. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with se- velamer increases serum fetuin-a concentration and improves endo- thelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68
7. David S, Kumpers P, Hellpap J et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 2009; 53: 770-778
8. Kielstein JT, Boger RH, Bode-Boger SM et al. Asymmetric dimethy- larginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600
9. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202
10. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end- stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
11. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965 (Pubitemid 351767576)
12. Roberts MA, Hare DL, Ratnaike S et al. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006; 48: 341-360
13. Yilmaz MI, Saglam M, Carrero JJ et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothe- lial damage? Clin Transplant 2009; 23: 241-248
14. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-1169
15. Fam NP, Verma S, Kutryk M et al. Clinician guide to angiogenesis. Circulation 2003; 108: 2613-2618
16. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angio- poietin-1 in vascular protection. Circ Res 2006; 98: 1014-1023
17. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-558
18. Kim I, Kim HG, So JN et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ Res 2000; 86: 24-29
19. Fiedler U, Scharpfenecker M, Koidl S et al. The Tie-2 ligand angio- poietin-2 is stored in and rapidly released upon stimulation from en- dothelial cell Weibel-Palade bodies. Blood 2004; 103: 4150-4156
20. Huang YQ, Li JJ, Hu L et al. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothe- lial cells. Blood 2002; 99: 1646-1650
21. Fiedler U, Reiss Y, Scharpfenecker M et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-239
22. Scharpfenecker M, Fiedler U, Reiss Y et al. The Tie-2 ligand angio- poietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118: 771-780
23. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothe- lial damage/dysfunction and atherosclerosis. Atherosclerosis 2005; 180: 113-118
24. Nykanen AI, Krebs R, Saaristo A et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003; 107: 1308-1314
25. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110: 2355-2360
26. Kumpers P, David S, Haubitz M et al. The Tie2 receptor antagonist angiopoietin-2 facilitates vascular inflammation in systemic lupus er- ythematosus. Ann Rheum Dis 2008; 68: 1638-1643
27. Kumpers P, Lukasz A, David S et al. Excess circulating angiopoietin- 2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008; 12: R147
28. Parikh SM, Mammoto T, Schultz A et al. Excess circulating angio- poietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3: e46
29. Kumpers P, Hellpap J, David S et al. Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrol Dial Transplant 2009; 24: 1845-1850
30. Kielstein JT, Boger RH, Bode-Boger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176
31. Grubb A, Nyman U, Bjork J et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 2005; 51: 1420-1431
32. Lukasz A, Hellpap J, Horn R et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care 2008; 12: R94
33. Martens-Lobenhoffer J, Bode-Boger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric di- methylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006; 52: 488-493
34. Kielstein JT, Salpeter SR, Buckley NS et al. Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants. Kidney Blood Press Res 2008; 31: 259-267
35. Kumpers P, Hafer C, David S et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med 2010; 36: 462-470
36. Post S, Peeters W, Busser E et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 2008; 45: 244-250
37. Patel JV, Lim HS, Varughese GI et al. Angiopoietin-2 levels as a bio- marker of cardiovascular risk in patients with hypertension. Ann Med 2008; 40: 215-222
38. David S, Kumpers P, Lukasz A et al. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens 2009; 27: 1641-1647